{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:38:38Z","timestamp":1761129518883},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13054-018-1948-6","type":"journal-article","created":{"date-parts":[[2018,1,26]],"date-time":"2018-01-26T14:42:54Z","timestamp":1516977774000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Do we need new trials of procalcitonin-guided antibiotic therapy?"],"prefix":"10.1186","volume":"22","author":[{"given":"Thiago","family":"Lisboa","sequence":"first","affiliation":[]},{"given":"Jorge","family":"Salluh","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Povoa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2018,1,27]]},"reference":[{"key":"1948_CR1","doi-asserted-by":"crossref","unstructured":"Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018;18(1):95\u2013107.","DOI":"10.1016\/S1473-3099(17)30592-3"},{"issue":"11","key":"1948_CR2","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1093\/cid\/cix179","volume":"64","author":"DC Chu","year":"2017","unstructured":"Chu DC, Mehta AB, Walkey AJ. Practice patterns and outcomes associated with procalcitonin use in critically ill patients with sepsis. Clin Infect Dis. 2017;64(11):1509\u201315.","journal-title":"Clin Infect Dis"},{"issue":"1 Suppl","key":"1948_CR3","doi-asserted-by":"publisher","first-page":"S80","DOI":"10.1097\/CCM.0b013e3181922bf4","volume":"37","author":"J Takala","year":"2009","unstructured":"Takala J. Better conduct of clinical trials: the control group in critical care trials. Crit Care Med. 2009;37(1 Suppl):S80\u201390.","journal-title":"Crit Care Med"},{"issue":"19","key":"1948_CR4","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1001\/jama.290.19.2588","volume":"290","author":"J Chastre","year":"2003","unstructured":"Chastre J, Wolff M, Fagon JY, et al. Comparison of 8 vs 15\u00a0days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA. 2003;290(19):2588\u201398.","journal-title":"JAMA"},{"issue":"5","key":"1948_CR5","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1378\/chest.125.5.1791","volume":"125","author":"ST Micek","year":"2004","unstructured":"Micek ST, Ward S, Fraser VJ, Kollef MH. A randomized controlled trial of an antibiotic discontinuation policy for clinically suspected ventilator-associated pneumonia. CHEST. 2004;125(5):1791\u20139.","journal-title":"CHEST"},{"issue":"3","key":"1948_CR6","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1097\/01.CCM.0000114814.62759.06","volume":"32","author":"HJ Silverman","year":"2004","unstructured":"Silverman HJ, Miller FG. Control group selection in critical care randomized controlled trials evaluating interventional strategies: an ethical assessment. Crit Care Med. 2004;32(3):852\u20137.","journal-title":"Crit Care Med"},{"issue":"10","key":"1948_CR7","doi-asserted-by":"publisher","first-page":"2336","DOI":"10.1097\/CCM.0b013e31828e969f","volume":"41","author":"CF Oliveira","year":"2013","unstructured":"Oliveira CF, Botoni FA, Oliveira CR, et al. Procalcitonin versus C-reactive protein for guiding antibiotic therapy in sepsis: a randomized trial. Crit Care Med. 2013;41(10):2336\u201343.","journal-title":"Crit Care Med"},{"issue":"8","key":"1948_CR8","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1007\/s00134-008-1112-x","volume":"34","author":"CE Luyt","year":"2008","unstructured":"Luyt CE, Combes A, Reynaud C, et al. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med. 2008;34(8):1434\u201340.","journal-title":"Intensive Care Med"},{"issue":"1","key":"1948_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13613-016-0134-8","volume":"6","author":"P P\u00f3voa","year":"2016","unstructured":"P\u00f3voa P, Martin-Loeches I, Ramirez P, et al. Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study. Ann Intensive Care. 2016;6(1):32.","journal-title":"Ann Intensive Care"},{"issue":"9713","key":"1948_CR10","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/S0140-6736(09)61879-1","volume":"375","author":"L Bouadma","year":"2010","unstructured":"Bouadma L, Luyt C, Tubach F, et al. Use of procalcitonin to reduce patients' exposure to antibiotics in intensive care units (PRORATA trial): a multicentre randomised controlled trial. Lancet. 2010;375(9713):463\u201374.","journal-title":"Lancet"},{"key":"1948_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1097\/CCM.0b013e3181692966","volume":"36","author":"J Amour","year":"2008","unstructured":"Amour J, Birenbaum A, Langeron O, et al. Influence of renal dysfunction on the accuracy of procalcitonin for the diagnosis of postoperative infection after vascular surgery. Crit Care Med. 2008;36:1147\u201354.","journal-title":"Crit Care Med."},{"key":"1948_CR12","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00134-009-1681-3","volume":"36","author":"N Mongardon","year":"2010","unstructured":"Mongardon N, Lemiale V, Perbet S, et al. Value of procalcitonin for diagnosis of early onset pneumonia in hypothermia-treated cardiac arrest patients. Intensive Care Med. 2010;36:92\u20139.","journal-title":"Intensive Care Med."},{"key":"1948_CR13","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1177\/0310057X0203000302","volume":"30","author":"AA Dahaba","year":"2002","unstructured":"Dahaba AA, Elawady GA, Rehak PH, List WF. Procalcitonin and proinflammatory cytokine clearance during continuous venovenous haemofiltration in septic patients. Anaesth Intensive Care. 2002;30:269\u201374.","journal-title":"Anaesth Intensive Care."},{"key":"1948_CR14","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00134-003-1664-8","volume":"29","author":"AA Dahaba","year":"2003","unstructured":"Dahaba AA, Rehak PH, List WF. Procalcitonin and C-reactive protein plasma concentrations in nonseptic uremic patients undergoing hemodialysis. Intensive Care Med. 2003;29:579\u201383.","journal-title":"Intensive Care Med."},{"key":"1948_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/1471-2334-8-163","volume":"8","author":"PE Charles","year":"2008","unstructured":"Charles PE, Ladoire S, Snauwaert A, et al. Impact of previous sepsis on the accuracy of procalcitonin for the early diagnosis of blood stream infection in critically ill patients. BMC Infect Dis. 2008;8:163.","journal-title":"BMC Infect Dis."},{"key":"1948_CR16","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1378\/chest.07-0175","volume":"132","author":"D Stolz","year":"2007","unstructured":"Stolz D, Stulz A, M\u00fcller B, et al. BAL neutrophils, serum procalcitonin and C-reactive protein to predict bacterial infection in the immunocompromised host. Chest. 2007;132:504\u201314.","journal-title":"Chest."},{"issue":"3","key":"1948_CR17","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/cc13870","volume":"18","author":"JI Salluh","year":"2014","unstructured":"Salluh JI, Nobre V, Povoa P. Using procalcitonin to guide antimicrobial duration in sepsis: asking the same questions will not bring different answers. Crit Care. 2014;18(3):142.","journal-title":"Crit Care"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-018-1948-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T21:23:50Z","timestamp":1570656230000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-018-1948-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,27]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1948"],"URL":"https:\/\/doi.org\/10.1186\/s13054-018-1948-6","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,27]]},"assertion":[{"value":"22 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"17"}}